Begin main content
CADTH Document Viewer

Common Acronyms for All Who Are New to CADTH

January 2019

To make it faster and easier for interested individuals to understand CADTH recommendations, reports, and CADTH Symposium presentations, we’d like to equip you with the meanings of these common acronyms. Welcome to the language of HTA and CADTH.

Acronym

What It Stands For

Details

AE

adverse event

An unwanted and usually harmful occurrence following treatment

BIA

budget impact analysis

Used to estimate the impact of adding a drug, device, or procedure to a public formulary or budget, based on cost and the number of people likely to receive treatment within a specific period of time

BSC

best supportive care

When the aim is to relieve symptoms and improve quality of life, rather than cure the disease

CADTH

Canadian Agency for Drugs and Technologies in Health

An independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system

CDEC

CADTH Canadian Drug Expert Committee

The expert committee of the CADTH Common Drug Review program that makes drug reimbursement recommendations

CDR

CADTH Common Drug Review

Reviews drugs and makes reimbursement recommendations to Canada's public drug plans

CI

confidence interval

The range around a result within which we would expect (with 90%, 95%, or 99% confidence) the true value to lie; the true value, however, may still lie outside this range

COI

conflict of interest

When judgment about one activity may be influenced, or be seen to be influenced, by competing interests or activity; COI may be intellectual, financial, or personal

CDx

companion diagnostic

Biomarker test used to identify if a select drug is likely to provide benefit for a particular patient before treatment begins

CEA

cost-effectiveness analysis

Used in economic evaluations to compare treatments that differs in the magnitude of their outcomes; outcomes are expressed in natural terms such as life-years gained or adverse events avoided

CGP

CADTH pCODR Clinical Guidance Panel

Responsible for interpreting the clinical data and developing conclusions for the Clinical Guidance Report as part the CADTH pan-Canadian Oncology Drug Review (pCODR); panels and members vary depending upon the type of cancer the drug reviewed treats

CMA

cost-minimization analysis

Used in economic evaluations to compare treatments that have similar clinical outcomes

CUA

cost-utility analysis

Used in economic evaluations to compare treatments when the outcomes are different; outcomes are expressed in quality-adjusted life-years to allow comparison between health technologies

DPAC

CADTH Drug Policy Advisory Committee

Representatives from public drug plans meet to provide strategic advice to CADTH on drug policy issues

EGP

CADTH pCODR Economic Guidance Panel

Responsible for assessing the economic evidence in the pCODR program

EQ-5D

EuroQol 5-Dimensions questionnaire

Used to measure health-related quality of life determined by an individual’s level of functioning on five aspects of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression

FPT

federal/provincial/territorial

CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec

HC

Health Canada

The federal department responsible for helping the people of Canada maintain and improve their health

HRQoL

health-related quality of life

Aspects of quality of life that are affected by illness and its treatment, including physical, psychological, and social functioning

HTA

health technology assessment

Systematically evaluates the direct and intended effects of a health technology, as well as its indirect and unintended consequences; generally done to help others make a decision on a technology’s use or purchase

HTAi

Health Technology
Assessment international

A scientific and professional society for all those who produce, use, or encounter HTA (including patients and citizens)

HTERP

CADTH Health Technology Expert Review Panel

Develops guidance on medical devices and diagnostic tests for Canadian health care decision-makers

HTM

health technology management

Management of drug and non-drug health technologies from pre-market development, to adoption and use, to obsolescence

ICER

incremental cost-effectiveness ratio

The result of a cost-effective analysis; the ratio is of the difference between the costs (in dollars) of two treatments and the difference in the outcomes

ICUR

incremental cost-utility ratio

Similar to ICER; costs are measured in dollars and benefits are measured in quality-adjusted life-years

INAHTA

International Network of Agencies for Health Technology Assessment

A global network of public HTA agencies that promotes and supports cooperation, information sharing, and capacity building in HTA

INESSS

Institut national d’excellence en santé et en services sociaux

Provides Quebec’s health care decision-makers with objective evidence on the adoption, use, and public-plan coverage of technologies, medications, and interventions; and develops guides to clinical practice for their optimal use

KMLO

CADTH Knowledge Mobilization and Liaison Officer team

Provides support to understand decision-makers’ evidence needs, and provides tools and advice to turn evidence into action

LY

life-years

Estimate of the years of life the average person lives as a result of a health technology

MCID

minimal clinically important difference

Used to describe the smallest change in a treatment outcome that patients would identify as important and which might lead to a change in treatment

NOC

Notice of Compliance

Authorization given by Health Canada when regulatory requirements are met, allowing a pharmaceutical company to market a drug in Canada

PAC

CADTH pCODR Advisory Committee

Provides strategic advice on cancer-specific issues to CADTH to ensure the pCODR program meets the needs of the provincial and territorial governments, and cancer agencies

PAG

CADTH pCODR Provincial Advisory Group

Representatives from public drug plans and provincial cancer agencies provide operational advice to ensure that the pCODR process and recommendations meet the evidence needs of decision-makers to guide funding decisions

pCODR

CADTH pan-Canadian Oncology Drug Review

Reviews cancer drugs and makes reimbursement recommendations to Canada's public drug plans and provincial cancer agencies

pCPA

pan-Canadian Pharmaceutical Alliance

Negotiates with pharmaceutical companies to achieve greater value on drugs for publicly funded drug plans

pERC

CADTH pCODR Expert Review Committee

The expert committee of the CADTH pan-Canadian Oncology Drug Review

POC

point of care

Point-of-care testing happens at or near where a patient is located rather than sending test samples to a medical laboratory

PMPRB

Patented Medicine Prices Review Board

Ensures the prices of patented medicines sold in Canada are not excessive compared to prices in other similar countries

PRO

patient-reported outcome

Information gathered directly from patients about how they feel or function

QALY

quality-adjusted life-year

Estimate of duration and quality of survival for an individual over an assumed time period

RCT

randomized controlled trial

A study design that randomly assigns participants into different treatment groups

RFA

Request for Advice

A formal process that enables drug plans to seek advice about a previous CDEC or pERC recommendation

RHA

Regional Health Authority

How Canadian provincial governments administer and deliver public health care to residents; these may also be known as Health Authorities, or collectively as a Health Network or Local Health Integration Network (LHIN)

RR

CADTH Rapid Response

A CADTH report that provides health care decision-makers with up-to-date evidence tailored to meet specific needs

SA

CADTH Scientific Advice

A program that offers pharmaceutical companies advice on their early drug development plans from an HTA perspective

SEB

subsequent entry biologic

A new version of a biologic drug sold after the patent for the biologic drug has expired; also referred to as a biosimilar

SF-36

Short Form Health Survey 36-item questionnaire

A Medical Outcomes Study questionnaire of overall health status that assesses functional status, well-being, and quality of life

WDAE

withdrawal due to adverse event

Any adverse event that results in the patient stopping taking the drug during a clinical trial


More Resources

HTAi consumer and patient glossary: a guide to words used in HTA available from the HTAi Interest Group on Patient and Citizen Involvement

http://www.htai.org/interest-groups/patient-and-citizen-involvement.html

International Network of Agencies for Health Technology Assessment Glossary, a collaborative effort between the International Network of Agencies for Health Technology Assessment (INAHTA), Health Technology Assessment international (HTAi), and other partner organizations

http://htaglossary.net